

VIRTUAL FORMAT
CEST Time

PROGRAMME OF LIVE SESSIONS: CEST timing

The programme below will take place live. This time schedule corresponds to **CEST timing**. [Click here: https://www.calculator.net/time-zone-calculator.html](https://www.calculator.net/time-zone-calculator.html) to adapt the CEST time schedule to your own time zone.

If you want to ask questions during the Panel Discussions, please make sure that you join us at the times indicated below.

Please also note that the Meet the Expert sessions and the Mentored Poster Walk will take place 100% live. To interact you must be online at the times indicated in the programme below.

Thank you for joining us. We wish you a good meeting



**ESH Translational Research E-Conference
LYMPHOID MALIGNANCIES**

October 14-17, 2021

Chairpersons: Michael Hallek (Cologne), Georg Lenz (Münster), Laurie Sehn (Vancouver), Louis Staudt (Bethesda)

Advisory Board: Barbara Eichhorst (Cologne), Ricardo Dalla-Favera (New York), Frank Morschhauser (Lille), Laura Pasqualucci (New York), Stephan Stilgenbauer (Ulm), Andrei Thomas-Tikhonenko (Philadelphia)

Thursday, October 14, 2021

15:30–15:40 Welcome

SESSION I – B-cell development and lymphomagenesis

Chairs: Ralf Küppers (Essen) & Laura Pasqualucci (New York)

15:40-15:45	Introduction	
15:45-16:05	BCR signaling in mature and malignant B-cells	Klaus Rajewsky (Berlin)
16:05-16:25	Mechanisms of the GCR and their involvement in lymphomagenesis	Laura Pasqualucci (New York)
16:25-16:45	Pathogenesis of Hodgkin lymphoma	Ralf Küppers (Essen)
16:45-17:05	Dissecting GCB DLBCL and its therapeutic implications	David Scott (Vancouver)

BRIEF ORAL COMMUNICATION:

17:05-17:12 *The Alternative RelB NFkB Subunit Is a Novel Critical Player in Diffuse Large B-Cell Lymphoma* *Véronique Baud (Paris)*

17:12-17:45 *Panel discussion*

17:45-17:55 *Coffee Break*

SESSION II – Genetics of malignant lymphomas and clonal evolution

Chairs: Margaret Shipp (Boston) & Louis Staudt (Bethesda)

17:55-18:00 Introduction

18:00-18:20 The genetic landscape of mantle cell lymphoma *Elias Campo (Barcelona)*

18:20-18:40 Novel molecular subtypes of aggressive lymphomas *Margaret Shipp (Boston)*

18:40-19:00 Rational development of combination therapies for lymphoma *Louis Staudt (Bethesda)*

19:00-19:20 Targeting genetic alterations in lymphoma *Andrew Davies (Southampton)*

BRIEF ORAL COMMUNICATION:

19:20-19:27 *Outcome Prediction in CLL By Integration of Serial MRD: The Refined Continuous Individualized Risk Index (CIRI2-CLL)* *Othman Al-Sawaf (Cologne)**

19:27-20:00 *Panel discussion*

Friday, October 15, 2021

12:50-13:50 Simultaneous Meet the Expert sessions (Clinical & Non-clinical)

- **CLL and indolent lymphoma** – José Ignacio Martín-Subero (Barcelona) & John Seymour (Melbourne)
- **Pathogenesis and kinase inhibitors in lymphoma** – Georg Lenz (Münster) & Louis Staudt (Bethesda)

SESSION III – Epigenetics in malignant lymphomas

Chairs: Ari Melnick (New-York) & Franck Morschhauser (Lille)

14:00-14:05 Introduction

14:05-14:25 Role of epigenetic aberrations in DLBCL *Ari Melnick (New York)*

14:25-14:45 Epigenetic alterations in mantle cell lymphoma *José Ignacio Martín-Subero (Barcelona)*

14:45-15:05 Epigenetics in T-cell lymphoma *Teresa Palomero (New York)*

15:05-15:25 Therapeutic potential of targeting epigenetic regulators *Franck Morschhauser (Lille)*

BRIEF ORAL COMMUNICATION:

15:25-15:32 *Sequential Inverse Dysregulation of the RNA Helicases DDX3X and DDX3Y Facilitates MYC-Driven Lymphomagenesis.* Daniel Hodson (Cambridge)

15:32-16:00 *Panel discussion*

16:00-16:10 *Coffee Break*

SESSION IV – Deregulated proteome and metabolome

Chairs: Kojo Elenitoba Johnson (Philadelphia) & Thomas Oellerich (Frankfurt)

16:10-16:15 Introduction

16:15-16:35 Pathogenetic proteomic alterations in lymphoma Thomas Oellerich (Frankfurt)

16:35-16:55 Targeting metabolism in T cell lymphoma Andrew Intlekofer (New York)

16:55-17:15 Targeting the Proteome in T-cell lymphoma Kojo Elenitoba Johnson (Philadelphia)

BRIEF ORAL COMMUNICATION:

17:15-17:22 *The MYC/MIZ1 Complexes Are Required for Germinal Center B Cell Lymphomagenesis* Arief Gunawan (London)*

17:22-17:50 *Panel discussion*

SESSION V – Single cell analyses, circulating tumor DNA, MRD

Chairs: Dan Landau (New York) & Bertrand Nadel (Marseille)

17:50-17:55 Introduction

17:55-18:15 Single cell analyses in lymphoma Bertrand Nadel (Marseille)

18:15-18:35 Single cell analyses in CLL Dan Landau (New York)

18:35-18:55 Circulating tumor DNA in aggressive lymphomas David Kurtz (Stanford)

18:55-19:15 Role of ctDNA, MRD in the clinic Andy Rawstron (Leeds)

BRIEF ORAL COMMUNICATION:

19:15-19:22 *Clinical Application of an Ex-Vivo Platform to Guide the Choice of Drug Combinations in Relapsed/Refractory Lymphoma; A Prospective Study* Anand D. Jeyasekharan (Singapore)

19:22-19:50 *Panel discussion*

13:20-14:20 Mentored Poster Walk

14:30-15:30 **SATELITTE SYMPOSIUM:**

Title: Inhibition of Bruton's Tyrosine Kinase (BTK) – a key approach to manage and treat indolent B-cell lymphomas

Chair: Véronique Leblond

Speakers: Christian Buske, Marie José Kersten & Steven Treon

This symposium is organized and funded by BeiGene.

SESSION VI – Oncogenic signaling pathways

Chairs: Georg Lenz (Münster) & Adrian Wiestner (Bethesda)

15:35-15:40 Introduction

15:40-16:00 Role of oncogenic BCR signaling in aggressive lymphomas James D. Phelan (Bethesda)

16:00-16:20 Addiction to PI3K isoforms in DLBCL Georg Lenz (Münster)

16:20-16:40 Oncogenic signaling in CLL Adrian Wiestner (Bethesda)

16:40-17:00 Oncogenic signaling in T-cell lymphoma Stephan Mathas (Berlin)

BRIEF ORAL COMMUNICATION:

17:00-17:07 *Ibrutinib Blocks CD40 Signalling in Malignant B Cells By Reducing TRAF4 Levels* Marek Mraz (Brno)

17:07-17:30 *Panel discussion*

17:40-18:40 **SATELITTE SYMPOSIUM:**

Title: Precision medicine in B-cell Lymphoid malignancies: is it possible ?

Chair: Kostas Stamatopoulos (Greece)

Speakers: Gianluca Gaidanno (Italy), Catherine Thieblemont (France) & Steven Treon (USA)

Satellite Symposium sponsored by Janssen.

18:45-19:45 **Simultaneous Meet the Expert sessions (Clinical & Non-clinical)**

- **Biology and genomics and clonal evolution of lymphoma** – Elias Campo (Barcelona) & David Kurtz (Stanford)
- **DLBCL and MCL** – Laurie Sehn (Vancouver) & Frederick Locke (Tampa)

19:45-20:30 **Break**

SESSION VII – Utilizing oncogenic signaling therapeutically
Chairs: Laurie Sehn (Vancouver) & John Seymour (Melbourne)

20:30-20:35	Introduction	
20:35-20:55	Role of BCR inhibitors in the treatment of lymphoma	Wyndham Wilson (Bethesda)
20:55-21:15	Combining pathway inhibitors in the treatment of CLL	Michael Hallek (Cologne)
21:15-21:35	Targeting anti-apoptotic pathways beyond CLL	John Seymour (Melbourne)
21:35-21:55	Tailoring therapy in frontline DLBCL	Laurie Sehn (Vancouver)

BRIEF ORAL COMMUNICATION:

21:55-22:02	<i>Ibrutinib Related Expression Patterns in Chronic Lymphocytic Leukaemia Patients</i>	<i>Charlotte McDonald (Belfast)</i>
22:02-22:35	<i>Panel discussion</i>	

Sunday, October 17, 2021

14:00-15:00 SATELITTE SYMPOSIUM:

Title: Latest translational and clinical insights in DLBCL

Chair: Bjoern Chapuy (Goettingen)

Speakers: Bjoern Chapuy (Goettingen) & Marion Subklewe (Munich)

Satellite Symposium sponsored by Celgene, a Bristol-Myers Squibb Company.

SESSION VIII – Immunologic approaches in the treatment of lymphomas

Chairs: Ranjana Advani (Stanford) & Pier Luigi Zinzani (Bologna)

15:05-15:10	Introduction	
15:10-15:30	Utilizing checkpoint inhibitors	Pier Luigi Zinzani (Bologna)
15:30-15:50	Perspective of bispecific antibodies	Stephen Schuster (Philadelphia)
15:50-16:10	Update CAR T-cells	Caron Jacobson (Boston)
16:10-16:30	Targeting CD47 as a new treatment option for lymphoma	Ranjana Advani (Stanford)
16:30-16:50	CAR T-cell therapies in mantle cell lymphoma	Frederick Locke (Tampa)
16:50-17:10	Utilizing novel CAR T-cell constructs	Peter Borchmann (Cologne)

BRIEF ORAL COMMUNICATION:

17:10-17:17 *Antitumor Activity and Safety Profile of Subcutaneous Epcoritamab in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Dose-Escalation Data from the Epcore NHL-1 Trial*

*Pieterella Lugtenburg (Rotterdam)**

17:17-17:50 *Panel discussion*

17:50-18:00 *Closing Remarks*

***Pending confirmation**